**Disclosure of Financial Interest of Clinical Investigators**

Title of Clinical Study: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Principal Investigator: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Identity of Investigational Device: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

In compliance with the provisions of [21 CFR Part 54](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=54&showFR=1), Financial Disclosure by Clinical Investigators, I hereby disclose that I have participated in financial arrangements or hold financial interests as follows: *(Check all applicable boxes.)*

[ ] any financial arrangement entered into between the company (i.e., other than the University) that owns the investigational drug or device being evaluated in the above-named clinical study, whereby the value of the compensation to me for conducting or participating in the clinical study could be influenced by the outcome of the study;

[ ] any significant payments (i.e. *financial interests*) of other sorts from the company (i.e., other than the University) that owns the investigational drug or device being evaluated in the above-named clinical study; such as a grant to fund ongoing research, compensation in the form of equipment, retainer for ongoing consultation, or honoraria;

[ ] any *proprietary* interest in the investigational drug or device being evaluated in the above-named clinical study;

[ ] any significant[[1]](#footnote-1) *equity interest* held by me in the company (i.e., other than the University) that owns the investigational drug or device being evaluated in the above-named clinical study.

***Attach to this form the details of your financial arrangements and interests. Also attach to this form, a description of the steps (i.e., management plan) taken by your department chair and/or dean, the University, or the principal investigator of the clinical study to minimize the potential bias of clinical study results related to your disclosed financial arrangements or interests.***

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Name of Clinical Investigator (Printed or Typed)

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_

Signature of Clinical Investigator Date

1. A significant *equity interest* is defined under [21 CFR Sec. 54.2](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=54.2)(b) as any ownership interest, stock options, or other financial interest in a non-public company that owns the investigational drug or device, or equity worth more than $50,000 in any public company that owns the investigational drug or device. [↑](#footnote-ref-1)